
GKOS — Glaukos Corp
NYSE · Healthcare · Medical Devices
$179.13
+$2.43 (+1.38%)
Glaukos Corp (GKOS) is a medical devices company listed on NYSE. It is led by Thomas William Burns, based in One Glaukos Way, Aliso Viejo, CA, United States, 92656, with about 1,094 employees. Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Latest reported GKOS revenue for 2025-09-30 was $133.5M. Net income was -$16.2M. Revenue was up 7.6% from 2025-06-30 to 2025-09-30. GKOS currently screens at market cap $7.63B.
Use this GKOS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GKOS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GKOS SEC filings page. Lician reads the product cache first so this HTML stays unique to Glaukos Corp even when a live quote feed is slow.
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
GKOS Key Statistics
Market Cap
$7.63B
Volume
639,609
Previous Close
$185.65
Day Range
$179.20 – $187.14
P/B Ratio
11.16
EPS
-$2.77
Revenue
$383.48M
Net Income
-$146.37M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+21.9%
Profit Margin
-38.2%
Employees
1,094
GKOS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $383.48M | $314.71M | $71.23M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$146.37M | -$134.66M | -$99.19M |
| EPS (Diluted) | -$2.77 | -$2.78 | -$0.66 |
Total Assets
$974.76M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$169.63M
Operating Cash Flow
-$61.32M
Free Cash Flow
$0.00
Glaukos Corp Company Information
- Chairman & CEO
- Thomas William Burns
- Headquarters
- One Glaukos Way, Aliso Viejo, CA, United States, 92656
- Website
- www.glaukos.com
- Phone
- 949 367 9600
- IPO / Founded
- 2015-06-25
- Sector
- Healthcare
- Industry
- Medical Devices